Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Ireland-headquartered Elan Corp (NYSE: ELN) has entered a strategic business relationship to advance US drug discovery firm Proteostasis Therapeutics' platform for the discovery and development of disease-modifying, small-molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis (ALS), and a broad array of dementia-related diseases including Alzheimer's. 26 May 2011
Pharmaceutical
US health care giant Johnson & Johnson' (NYSE: JNJ) Switzerland-based Cilag GmbH International has entered a definitive agreements to acquire the over-the-counter (OTC) brands of India's J B Chemicals & Pharmaceuticals for the equivalent of around $260 million in cash. The transaction is anticipated to close by mid-2011, and JB has also signed a long-term agreement to supply Cilag with finished products for the acquired Russia/CIS OTC business. 25 May 2011
Pharmaceutical
US drug major Eli Lilly (NYSE: LLY) has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica, a newly-formed and privately-held biotechnology company. 24 May 2011
Pharmaceutical
Despite just yesterday again saying that it "has not agreed to any such an agreement," this morning Takeda (TSE: 4502) declared that it has in fact reached an accord to acquire Swiss independent drugmaker Nycomed, in a deal valuing the Zurich-headquartered company at 9.6 billion euros ($13.68 billion) on a cash-free, debt-free basis. 19 May 2011
Pharmaceutical
Following its acquisition of a majority stake in the Danish firm, India-based Ecron Acunova, a full-service international contact research organization, has merged with aCROnordic, specialized in Nordic clinical research. Ecron Acunova thereby extends its global activities and aCROnordic - now Ecron Acunova A/S - goes global. 19 May 2011
Pharmaceutical
Ireland-headquartered biopharmaceutical firm Shire (LSE: SHP) - best known for its attention-deficit hyperactivity disorder franchise - has signed an agreement to acquire privately-held USA-based regenerative medicine company Advanced BioHealing for $750 million in cash, financed from its existing cash. 18 May 2011
Pharmaceutical
CytRx completes sale of molecular chaperone assets to Orphazyme ApS in deal worth up to $120 million
US biopharma firm CytRx Corp (Nasdaq: CYTR) says that it has sold the worldwide rights to its molecular chaperone assets to privately-held Copenhagen, Denmark-based Orphazyme ApS. 18 May 2011
Pharmaceutical
Massachusetts, USA-based Histogenics Corp, a privately held regenerative medicine company, says that it has acquired Israeli firm ProChon Biotech in a stock-for-stock exchange. 18 May 2011
Pharmaceutical
Japan's Mitsui & Co said recently that it has decided to acquire a 100% stake in MBS Co Ltd, a wholly owned subsidiary of Mercian Corp (itself a unit of Kirin Holding). This will be achieved by demerger (absorption-type split) of Mercian's pharmaceutical and chemical businesses, and Mitsui and Mercian entered into a share transfer agreement in relation to this acquisition. No further financial terms were disclosed. 17 May 2011
Pharmaceutical
Last week saw Japan's largest drugmaker Takeda (TSE: 4502) take the unusual step of actually commenting on rumors when these surfaced about a potential $10-$14 billion acquisition of privately-held Swiss pharmaceutical firm Nycomed (The Pharma Letter May 12 and 13). However, the logic and value of such a deal nevertheless stands, says an analyst at Datamonitor, whose comments and analysis of both companies' businesses follow for the interests of our readers. And who knows, a deal could eventually still be struck. 16 May 2011
Pharmaceutical
Takeda Pharmaceutical (TSE: 4502), Japan's largest drugmaker, has emphatically denied that it is in advanced talks to acquire independent Swiss drugmaker Nycomed, as has been strongly rumored over the past few days (The Pharma Letter May 12). 13 May 2011
Pharmaceutical
US drugmaker Alkermes (Nasdaq: ALKS) and Ireland-based Elan Corp (NYSE: ELN) revealed this morning that they have executed a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at around $960 million. Alkermes and EDT will be combined under a new holding company incorporated in Ireland, which will be named Alkermes plc. 9 May 2011
Pharmaceutical
Although German drugs and crop sciences major Bayer AG (BAY: DE) is fine with doing nothing, a 'merger of equals' could be contemplated, the firm's recently-appointed chief executive Marijn Dekkers told the Bloomberg news service in an interview this week. 5 May 2011
Pharmaceutical
Spanish health care group Grifols (GRLS: MC) and acquisition target Talecris Biotherapeutics (Nasdaq: TLCR) of the USA have signed a Consent Agreement with officials of the US Federal Trade Commission by means of which the conditions for the merger transaction between both companies are agreed. The Consent Agreement is subject to approval of the FTC Commissioners, who will be reviewing the matter. 3 May 2011
Pharmaceutical
Following earlier speculation, this morning, US diversified health care giant Johnson & Johnson (NYSE: JNJ) confirmed that it has reached agreement to acquire Switzerland-based orthopedic device maker Synthes (SYST: VX) for 159 Swiss francs per share, or $21.3 billion in total. 27 April 2011
Pharmaceutical
USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) says that it has acquired NovaMed Pharmaceuticals, a China-based specialty pharmaceutical company. The acquisition brings additional broad sales and marketing, as well as regulatory and extensive business capabilities and pharmaceutical assets in the regulatory approval stage to its growing and profitable China-focused specialty pharmaceutical business, the US drugmaker said. 21 April 2011
Pharmaceutical
With the aim of expanding its drug delivery offerings, USA-based drugs and medical device maker Baxter International (NYSE: BAX) says it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, a specialty pharmaceutical company based in King of Prussia, Pennsylvania. 20 April 2011
Pharmaceutical
Bulgaria's largest drugmaker Sopharma has acquired Belarusian pharmacy chain Tabina through its Latvian unit Briz, it said in a statement to the Bulgarian Stock Exchange (BSE), reported by the Sofia Echo. 20 April 2011
Pharmaceutical
US drug majors Merck & Co) and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc have reached finally agreement to amend the distribution rights to Remicade (infliximab) and follow-on drug Simponi (golimumab), which treat chronic inflammatory diseases such as rheumatoid arthritis. 18 April 2011
Pharmaceutical
Following up on a previously announced intention, UK pharma giant GlaxoSmithKline (LSE: GSK) says it has identified the non-core over-the-counter (OTC) medicines brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and the emerging markets. 18 April 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze